Navigation Links
Model-Based Drug Development 101, a new Xtalks webinar
Date:2/6/2013

Toronto, Canada (PRWEB) February 06, 2013

As the development of new drugs is becomes increasingly expensive and lengthy process, it’s clear that new approaches must be explored.

With model-based drug development (MBDD), mathematical models can be used early on to test extremely complex situations before deciding on a course of action. These models can identify the right dose, the right population, optimize clinical protocol, program, and portfolio designs, and compare candidates with existing drugs — ultimately providing better decisions and optimized returns.

Expert speakers will provide an overview of the basics of model based drug development and its practical applications — from electing the right dose and population to optimizing trial, program, and portfolio design.

Attendees will get a sense of how model- based drug development can help to:

  •     Improve communication across disciplines
  •     Utilize the many data domains to improve drug development
  •     Make better, quantitative, data-driven decisions

A live Q&A with the audience will follow the main presentation.

For more information about this event or to register, http://xtks.in/xto569-event

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
2. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
3. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
4. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
5. ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents
6. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
7. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
8. Idenix Reports Advancement of HCV Development Pipeline
9. Almost perfect: A breakthrough in superlens development
10. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
11. New Software from SRI Speeds Development of Genome-Scale Models for Drug and Fuel Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... BETHESDA, Md. , April 1, 2015 /PRNewswire/ ... development company committed to the fostering and monetization ... Markets LLC, a privately held full service global ... companies, recently issued an industry note featuring Spherix. ... McIlree , CFA, a Senior Analyst at Chardan, ...
(Date:4/1/2015)... CA (PRWEB) April 01, 2015 The concept ... loss, a multi-billion dollar industry. Founder of Fasciology, Ashley Black, ... an area of fat, instead of having to wait for ... Black claims that “ prior to fat cooling procedures, ... sculpting or contouring, was liposuction, which is a highly invasive ...
(Date:4/1/2015)... 2015 National recruitment firm Slone ... Brad Allen as Head of Sales at Optimal Medicine, ... market. , Allen brings over 20 years experience ... a number of companies including Dell Services Healthcare, Medsphere ... were a perfect fit for accomplishing the goals Optimal ...
(Date:3/31/2015)... 31, 2015 CytoSorbents Corporation (NASDAQ CM: ... purification to treat critically-ill and cardiac surgery patients ... and reports financial results for the fiscal year ... CytoSorb® product revenues were a record $3.1M, an ... CytoSorb® revenues of $0.8M Highlights for the Year ...
Breaking Biology Technology:Chardan Capital Issues Industry Note Covering Spherix 2Chardan Capital Issues Industry Note Covering Spherix 3Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 2Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 3Slone Partners Fills Head of Sales at Optimal Medicine 2CytoSorbents Reports Record 2014 Revenue 2CytoSorbents Reports Record 2014 Revenue 3CytoSorbents Reports Record 2014 Revenue 4CytoSorbents Reports Record 2014 Revenue 5CytoSorbents Reports Record 2014 Revenue 6CytoSorbents Reports Record 2014 Revenue 7CytoSorbents Reports Record 2014 Revenue 8CytoSorbents Reports Record 2014 Revenue 9CytoSorbents Reports Record 2014 Revenue 10CytoSorbents Reports Record 2014 Revenue 11
... Pharmaceuticals is,pleased to announce the introduction of ... on medically based aesthetics and,utilize the clinical ... of,science-based, result-oriented products., Vitivia(TM),s first product ... have long been recognized as important tools ...
... 27 Debiopharm Group,(Debiopharm), a global independent ... and particularly oncology, today,announced the establishment of ... Federale de Lausanne (EPFL), focusing on Signal ... million endowment, the objective,of the chair is ...
... combination vaccine against Ebola and Marburg viruses using ... infection in monkeys. Researchers from the U.S. ... report their results today (Feb. 26) at the ... in Baltimore, MD. , VLPs are one of ...
Cached Biology Technology:JSJ Pharmaceuticals Announces Launch of Aesthetic Division - Vitivia(TM) 2Debiopharm and EPFL Establish an Oncology Chair 2Combination vaccine protects monkeys from ebola and Marburg viruses 2
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... Researchers at Loyola University Chicago Stritch School of ... the National Institutes of Health to study vitamin D ... evaluate the relation between low vitamin D levels and ... disease. Evidence from numerous previous studies is "inconclusive ...
... N.C. Researchers at the University of North Carolina at ... and paste together different viruses in an effort to create ... clinical trial, the investigators found no side effects from using ... muscle protein in patients with muscular dystrophy. "This trial ...
... Bethesda, MDUsing magnetic resonance imaging (MRI) and nanoparticle technology, ... the growth of laboratory-engineered blood vessels after they have ... step toward ensuring that blood vessels, and possibly other ... taking hold and working as expected. Until now, there ...
Cached Biology News:Loyola receives NIH grant to study vitamin D deficiency in African populations 2Clinical trial for muscular dystrophy demonstrates safety of customized gene therapy 2Yale researchers develop a way to monitor engineered blood vessels as they grow in patients 2
Rabbit anti-phospho-EGFr (Tyr992) - Concentrate...
... PS603. Immunogen: Synthetic phosphopeptide ... the phosphorylated Ser603 residue of ... Specific for synapsin I when ... Reactivity: Rat (positive control: ...
CMRL Medium-1066 (1X) liquid...
... 11(R)-HETE is biosynthesized by the ... purpuratus, and the fresh water hydra, ... 11(R)-HETE relates to oocyte maturation and ... species.11(R)-HETE is also produced when aspirin-treated ...
Biology Products: